261 related articles for article (PubMed ID: 24114398)
1. Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm.
Kim K; Svedbom A; Luo X; Sutradhar S; Kanis JA
Osteoporos Int; 2014 Jan; 25(1):325-37. PubMed ID: 24114398
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of bazedoxifene incorporating the FRAX® algorithm in a European perspective.
Borgström F; Ström O; Kleman M; McCloskey E; Johansson H; Odén A; Kanis JA
Osteoporos Int; 2011 Mar; 22(3):955-65. PubMed ID: 20532482
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of bazedoxifene compared with raloxifene in the treatment of postmenopausal osteoporotic women.
Hiligsmann M; Ben Sedrine W; Reginster JY
J Bone Miner Res; 2013 Apr; 28(4):807-15. PubMed ID: 23165656
[TBL] [Abstract][Full Text] [Related]
4. An evaluation of the Fracture Risk Assessment Tool (FRAX®) as an indicator of treatment efficacy: the effects of bazedoxifene and raloxifene on vertebral, nonvertebral, and all clinical fractures as a function of baseline fracture risk assessed by FRAX®.
Kaufman JM; Palacios S; Silverman S; Sutradhar S; Chines A
Osteoporos Int; 2013 Oct; 24(10):2561-9. PubMed ID: 23595562
[TBL] [Abstract][Full Text] [Related]
5. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
[TBL] [Abstract][Full Text] [Related]
6. Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis.
Ström O; Jönsson B; Kanis JA
Osteoporos Int; 2013 Apr; 24(4):1491-502. PubMed ID: 23224141
[TBL] [Abstract][Full Text] [Related]
7. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of pharmacological fracture prevention for osteoporosis as prescribed in clinical practice in France, Germany, Italy, Spain, and the United Kingdom.
Svedbom A; Hadji P; Hernlund E; Thoren R; McCloskey E; Stad R; Stollenwerk B
Osteoporos Int; 2019 Sep; 30(9):1745-1754. PubMed ID: 31270592
[TBL] [Abstract][Full Text] [Related]
9. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX.
Kanis JA; Johansson H; Oden A; McCloskey EV
Bone; 2009 Jun; 44(6):1049-54. PubMed ID: 19254788
[TBL] [Abstract][Full Text] [Related]
10. The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX.
Borgström F; Ström O; Coelho J; Johansson H; Oden A; McCloskey EV; Kanis JA
Osteoporos Int; 2010 Mar; 21(3):495-505. PubMed ID: 19565175
[TBL] [Abstract][Full Text] [Related]
11. Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study.
Silverman SL; Chines AA; Kendler DL; Kung AW; Teglbjærg CS; Felsenberg D; Mairon N; Constantine GD; Adachi JD;
Osteoporos Int; 2012 Jan; 23(1):351-63. PubMed ID: 21779819
[TBL] [Abstract][Full Text] [Related]
12. Evaluation on the cost-effective threshold of osteoporosis treatment on elderly women in China using discrete event simulation model.
Ni W; Jiang Y
Osteoporos Int; 2017 Feb; 28(2):529-538. PubMed ID: 27581955
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries--an economic evaluation based on the fracture intervention trial.
Ström O; Borgström F; Sen SS; Boonen S; Haentjens P; Johnell O; Kanis JA
Osteoporos Int; 2007 Aug; 18(8):1047-61. PubMed ID: 17333449
[TBL] [Abstract][Full Text] [Related]
14. FRAX and its applications in health economics--cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example.
Ström O; Borgström F; Kleman M; McCloskey E; Odén A; Johansson H; Kanis JA
Bone; 2010 Aug; 47(2):430-7. PubMed ID: 20493983
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of denosumab versus oral alendronate for elderly osteoporotic women in Japan.
Mori T; Crandall CJ; Ganz DA
Osteoporos Int; 2017 May; 28(5):1733-1744. PubMed ID: 28210776
[TBL] [Abstract][Full Text] [Related]
16. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
[TBL] [Abstract][Full Text] [Related]
17. The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis.
Borgström F; Ström O; Coelho J; Johansson H; Oden A; McCloskey E; Kanis JA
Osteoporos Int; 2010 Feb; 21(2):339-49. PubMed ID: 19513577
[TBL] [Abstract][Full Text] [Related]
18. Cost-utility of long-term strontium ranelate treatment for postmenopausal osteoporotic women.
Hiligsmann M; Bruyère O; Reginster JY
Osteoporos Int; 2010 Jan; 21(1):157-65. PubMed ID: 19350339
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of romosozumab for the treatment of postmenopausal women with osteoporosis at high risk of fracture in Belgium.
Gielen E; Aldvén M; Kanis JA; Borgström F; Senior E; Willems D
Osteoporos Int; 2024 Jul; 35(7):1173-1183. PubMed ID: 38565690
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of implementing guidelines for the treatment of glucocorticoid-induced osteoporosis in Japan.
Moriwaki K; Fukuda H
Osteoporos Int; 2019 Feb; 30(2):299-310. PubMed ID: 30610244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
